Original post · Original
The article text is unavailable in this language; an existing version is shown.
Rohan Paul@rohanpaul_ai
> Anthropic now uses Claude inside real drug programs at 6 companies and runs its own, including muscular dystrophy work that could reach human trials as soon as late 2028.
> Claude handled far more than molecule ideas: it generated roughly 35K antibody designs in about a month, coordinated 11 outside labs for a one-person biotech, and caught 7 manufacturing issues human reviewers missed.
> The work remains mostly preclinical, though Anthropic’s in-house programs could put a drug into human trials as soon as late 2028.
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own.
In doing so, we’ve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
https://t.co/EVbxkdDTgJ
View this post on X ↗
· UTC+8